With fresh, positive data in hand, Biohaven now believes its medicine could be the first to receive FDA approval for spinocerebellar ataxia.
The company’s technology, which enables it to target viral proteins in their “prefusion” shape and skip a manufacturing step, could lead to vaccines that are more potent and easier to produce, said ...
Dr. Meg Richards from Panalgo discusses how real-world data is unlocking advancements in drug safety during pregnancy.